A Phase 1B Trial of Tarloxotinib and Sotorasib in Patients with KRAS G12C Mutations
For more information about the trial above please contact the study team:
Principal Investigator, Mariam Alexander, at email@example.com.
Study Coordinator, Alexandra Leitner, at firstname.lastname@example.org, or please call +1 843-792-1507.
Trial opened at the following institutions: Medical University of South Carolina